|
1
|
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
|
Proc Natl Acad Sci U S A
|
2010
|
2.86
|
|
2
|
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
|
Lancet Oncol
|
2008
|
2.70
|
|
3
|
Regulation of leukocyte recruitment by the long pentraxin PTX3.
|
Nat Immunol
|
2010
|
2.60
|
|
4
|
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis.
|
Science
|
2009
|
2.30
|
|
5
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
Blood
|
2007
|
2.05
|
|
6
|
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
|
Lancet Oncol
|
2008
|
1.64
|
|
7
|
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6.
|
J Immunol
|
2003
|
1.52
|
|
8
|
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
Haematologica
|
2002
|
1.47
|
|
9
|
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
|
Leuk Res
|
2013
|
1.42
|
|
10
|
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.
|
Eur J Pharmacol
|
2007
|
1.41
|
|
11
|
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.
|
Blood
|
2006
|
1.38
|
|
12
|
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.
|
Blood
|
2009
|
1.36
|
|
13
|
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.
|
Brain
|
2008
|
1.36
|
|
14
|
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
|
Blood
|
2011
|
1.35
|
|
15
|
Recombinant C1 inhibitor in brain ischemic injury.
|
Ann Neurol
|
2009
|
1.33
|
|
16
|
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.
|
J Immunol
|
2005
|
1.26
|
|
17
|
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
|
J Immunol
|
2011
|
1.24
|
|
18
|
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
|
Blood
|
2012
|
1.23
|
|
19
|
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
|
Cancer Res
|
2004
|
1.21
|
|
20
|
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
|
Clin Cancer Res
|
2009
|
1.21
|
|
21
|
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor.
|
J Immunol
|
2004
|
1.19
|
|
22
|
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo.
|
J Biol Chem
|
2013
|
1.18
|
|
23
|
On-chip manipulation of protein-coated magnetic beads via domain-wall conduits.
|
Adv Mater
|
2010
|
1.14
|
|
24
|
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways.
|
Blood
|
2007
|
1.12
|
|
25
|
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.
|
Biochemistry
|
2010
|
1.11
|
|
26
|
Gene therapy in epilepsy: the focus on NPY.
|
Peptides
|
2006
|
1.04
|
|
27
|
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity.
|
Neurobiol Dis
|
2011
|
1.04
|
|
28
|
Antiepileptic effects of botulinum neurotoxin E.
|
J Neurosci
|
2005
|
1.03
|
|
29
|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
1.03
|
|
30
|
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia.
|
Circulation
|
2012
|
1.03
|
|
31
|
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.
|
Blood
|
2002
|
1.02
|
|
32
|
The antidepressant mechanism of Hypericum perforatum.
|
Life Sci
|
2004
|
1.01
|
|
33
|
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
|
PLoS One
|
2011
|
1.00
|
|
34
|
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
|
Ann Hematol
|
2006
|
0.98
|
|
35
|
Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-Helicobacter pylori therapy.
|
Gastroenterology
|
2003
|
0.98
|
|
36
|
Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
|
J Peripher Nerv Syst
|
2007
|
0.97
|
|
37
|
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
|
J Clin Oncol
|
2004
|
0.97
|
|
38
|
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.
|
Blood
|
2011
|
0.97
|
|
39
|
Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans.
|
J Biol Chem
|
2012
|
0.97
|
|
40
|
The GTPase-activating protein RN-tre controls focal adhesion turnover and cell migration.
|
Curr Biol
|
2013
|
0.97
|
|
41
|
Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins.
|
Blood
|
2006
|
0.96
|
|
42
|
Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit.
|
Neuron
|
2012
|
0.96
|
|
43
|
WB4101-related compounds: new, subtype-selective alpha1-adrenoreceptor antagonists (or inverse agonists?).
|
J Med Chem
|
2006
|
0.95
|
|
44
|
Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways.
|
J Mol Biol
|
2008
|
0.95
|
|
45
|
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
|
Curr Pharm Des
|
2013
|
0.95
|
|
46
|
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
|
J Clin Oncol
|
2006
|
0.94
|
|
47
|
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.
|
J Biol Chem
|
2010
|
0.94
|
|
48
|
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
|
Blood
|
2013
|
0.93
|
|
49
|
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide.
|
Biomaterials
|
2010
|
0.92
|
|
50
|
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
|
Leuk Lymphoma
|
2011
|
0.91
|
|
51
|
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease.
|
ACS Nano
|
2012
|
0.91
|
|
52
|
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
|
Eur J Haematol
|
2008
|
0.91
|
|
53
|
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.
|
PLoS One
|
2011
|
0.90
|
|
54
|
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
|
Leuk Lymphoma
|
2010
|
0.89
|
|
55
|
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study.
|
Amyloid
|
2012
|
0.89
|
|
56
|
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
|
Leuk Res
|
2010
|
0.89
|
|
57
|
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
|
Ann Hematol
|
2012
|
0.88
|
|
58
|
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia.
|
Blood
|
2007
|
0.88
|
|
59
|
Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique.
|
Biosens Bioelectron
|
2010
|
0.88
|
|
60
|
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat.
|
J Mol Cell Cardiol
|
2002
|
0.88
|
|
61
|
Harnessing the liquid-phase exfoliation of graphene using aliphatic compounds: a supramolecular approach.
|
Angew Chem Int Ed Engl
|
2014
|
0.88
|
|
62
|
Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression.
|
Hematol J
|
2004
|
0.87
|
|
63
|
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.
|
Autophagy
|
2013
|
0.87
|
|
64
|
Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist.
|
Eur J Med Chem
|
2012
|
0.87
|
|
65
|
A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)₁₋₄₀ and Aβ₁₋₄₂ from the corresponding depsipeptides.
|
Anal Biochem
|
2010
|
0.87
|
|
66
|
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease.
|
ACS Nano
|
2012
|
0.86
|
|
67
|
Novel approaches for studying amyloidogenic peptides/proteins.
|
Curr Opin Pharmacol
|
2013
|
0.86
|
|
68
|
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
|
Cancer Chemother Pharmacol
|
2014
|
0.86
|
|
69
|
Immunopurification of pathological prion protein aggregates.
|
PLoS One
|
2009
|
0.86
|
|
70
|
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.
|
Haematologica
|
2013
|
0.85
|
|
71
|
Nanosized corners for trapping and detecting magnetic nanoparticles.
|
Nanotechnology
|
2009
|
0.85
|
|
72
|
APO866 activity in hematologic malignancies: a preclinical in vitro study.
|
Blood
|
2009
|
0.85
|
|
73
|
Sign control of magnetoresistance through chemically engineered interfaces.
|
Adv Mater
|
2014
|
0.85
|
|
74
|
Good gene, bad gene: new APP variant may be both.
|
Prog Neurobiol
|
2012
|
0.84
|
|
75
|
CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
|
Haematologica
|
2003
|
0.84
|
|
76
|
Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury.
|
ACS Nano
|
2013
|
0.84
|
|
77
|
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
|
Am J Hematol
|
2012
|
0.84
|
|
78
|
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.
|
Am J Hematol
|
2015
|
0.83
|
|
79
|
Dissociation of [3H]L-glutamate uptake from L-glutamate-induced [3H]D-aspartate release by 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid and 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic acid, two conformationally constrained aspartate and glutamate analogs.
|
Mol Pharmacol
|
2004
|
0.83
|
|
80
|
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
|
Clin Cancer Res
|
2013
|
0.83
|
|
81
|
Applications of surface plasmon resonance (SPR) for the characterization of nanoparticles developed for biomedical purposes.
|
Sensors (Basel)
|
2012
|
0.82
|
|
82
|
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
|
Br J Haematol
|
2007
|
0.82
|
|
83
|
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
|
Leuk Lymphoma
|
2012
|
0.81
|
|
84
|
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
|
Br J Haematol
|
2007
|
0.81
|
|
85
|
CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence.
|
Ann Hematol
|
2009
|
0.81
|
|
86
|
The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue.
|
Biomaterials
|
2011
|
0.81
|
|
87
|
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
|
Muscle Nerve
|
2008
|
0.80
|
|
88
|
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.
|
Amyloid
|
2013
|
0.80
|
|
89
|
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
|
Ann Hematol
|
2009
|
0.80
|
|
90
|
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
|
Leuk Res
|
2011
|
0.79
|
|
91
|
Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.
|
Eur J Haematol
|
2004
|
0.79
|
|
92
|
Structure-affinity studies for a novel series of homochiral naphtho and tetrahydronaphtho analogues of alpha 1 antagonist WB-4101.
|
Bioorg Med Chem
|
2004
|
0.79
|
|
93
|
Epitope scanning indicates structural differences in brain-derived monomeric and aggregated mutant prion proteins related to genetic prion diseases.
|
Biochem J
|
2013
|
0.79
|
|
94
|
Functional analysis of a murine monoclonal antibody against the repetitive region of the fibronectin-binding adhesins fibronectin-binding protein A and fibronectin-binding protein B from Staphylococcus aureus.
|
FEBS J
|
2010
|
0.79
|
|
95
|
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
|
Ann Hematol
|
2004
|
0.79
|
|
96
|
QSAR study for a novel series of ortho monosubstituted phenoxy analogues of alpha1-adrenoceptor antagonist WB4101.
|
Bioorg Med Chem
|
2005
|
0.79
|
|
97
|
Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
|
Br J Haematol
|
2007
|
0.78
|
|
98
|
New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide.
|
Anal Chem
|
2010
|
0.78
|
|
99
|
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.
|
Leuk Lymphoma
|
2006
|
0.78
|
|
100
|
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.
|
Curr Cancer Drug Targets
|
2013
|
0.78
|
|
101
|
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
102
|
New insights into biology of chronic myeloid leukemia: implications in therapy.
|
Curr Cancer Drug Targets
|
2013
|
0.78
|
|
103
|
Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake.
|
J Pharmacol Exp Ther
|
2008
|
0.78
|
|
104
|
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas.
|
Ann Hematol
|
2007
|
0.77
|
|
105
|
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
|
Br J Haematol
|
2007
|
0.77
|
|
106
|
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
|
Oncol Rep
|
2005
|
0.77
|
|
107
|
St. John's wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects.
|
Curr Drug Metab
|
2009
|
0.76
|
|
108
|
Substrate inhibitors and blockers of excitatory amino acid transporters in the treatment of neurodegeneration: critical considerations.
|
Eur J Pharmacol
|
2003
|
0.76
|
|
109
|
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
|
Ann Hematol
|
2014
|
0.76
|
|
110
|
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.
|
Leuk Lymphoma
|
2012
|
0.76
|
|
111
|
Potential antidepressant properties of IDN 5491 (hyperforin-trimethoxybenzoate), a semisynthetic ester of hyperforin.
|
Eur Neuropsychopharmacol
|
2005
|
0.76
|
|
112
|
Tetrahydro-β-carboline-based spirocyclic lactam as type II' β-turn: application to the synthesis and biological evaluation of somatostatine mimetics.
|
J Org Chem
|
2013
|
0.76
|
|
113
|
A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10.
|
PLoS One
|
2013
|
0.75
|
|
114
|
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
|
Biosci Trends
|
2017
|
0.75
|
|
115
|
AMIL survey (anemia in Internal Medicine in Liguria).
|
Ann Ital Med Int
|
2003
|
0.75
|
|
116
|
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
|
Ann Hematol
|
2013
|
0.75
|
|
117
|
[Mediastinal syndrome: clinical presentation of lymphoma. Report of a case of Hodgkin's lymphoma and a case of non-Hodgkin's lymphoma with similar presentation].
|
Ann Ital Med Int
|
2003
|
0.75
|
|
118
|
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
|
Oncol Rep
|
2009
|
0.75
|
|
119
|
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
|
Eur J Haematol
|
2002
|
0.75
|
|
120
|
[Moschkowitz's disease].
|
Ann Ital Med Int
|
2005
|
0.75
|
|
121
|
Chronic myeloid leukemia: reaching for the cure.
|
Curr Cancer Drug Targets
|
2013
|
0.75
|
|
122
|
New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: the role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome.
|
Eur J Cancer
|
2012
|
0.75
|
|
123
|
[Pharmacologic characteristics and clinical activity of human rituximab anti-CD20 monoclonal antibody].
|
Ann Ital Med Int
|
2003
|
0.75
|
|
124
|
A novel spirocyclic tropanyl-Δ²-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake.
|
Bioorg Med Chem
|
2012
|
0.75
|
|
125
|
6-methoxy-7-benzofuranoxy and 6-methoxy-7-indolyloxy analogues of 2-[2-(2,6-Dimethoxyphenoxy)ethyl]aminomethyl-1,4-benzodioxane (WB4101):1 discovery of a potent and selective α1D-adrenoceptor antagonist.
|
J Med Chem
|
2013
|
0.75
|
|
126
|
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
127
|
Charge and spin transport in PEDOT:PSS nanoscale lateral devices.
|
Nanotechnology
|
2013
|
0.75
|
|
128
|
Pharmacology in the high tech age--new developments, opportunities and limitations.
|
Curr Opin Pharmacol
|
2013
|
0.75
|
|
129
|
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study.
|
Ann Hematol
|
2011
|
0.75
|